Tenosynovial giant cell tumor (TGCT, also known as pigmented villonodular synovitis [PVNS]), is a rare tumor, which can cause pain, disability and reduced work productivity, with substantial economic impact (e.g., sick leave, medical costs) and detrimental effects on QoL.1–3
Patients face a challenging journey, with delayed diagnosis and limited treatment options, often leaving them stuck in a surgery loop.1,3,4
The International Clinical Consensus suggests that TGCT treatment should be managed within expert centers or reference networks by a dedicated, experienced sarcoma multidisciplinary treatment team.2
View the International Clinical Consensus here
LEARN FROM THE TGCT MEDICAL EXPERTS
Watch these medical expert perspectives to learn more about TGCT. You can also visit our MEDICAL EXPERT INSIGHTS page to explore additional opinions and insights.
Why is it important to increase awareness of TGCT among HCPs and patients?
Click here to find out more about TGCT 
Click here to find out
Click here to find outPVNS, pigmented villonodular synovitis; QoL, quality of life; TGCT, tenosynovial giant cell tumor.
References:
- Berthnal NM, et al. Orphanet J Rare Dis. 2021;16(1):191.
- Stacchiotti S, et al. Cancer Treat Rev. 2023;112:102491.
- Lopez-Bastida J, et al. Orphanet J Rare Dis. 2021;16(1):294.
- Ansel S, et al. J Med Case Rep. 2023;17(1):419.
DCPH-P02491 | July 2026